These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35890173)

  • 1. Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.
    Meqbil YJ; van Rijn RM
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
    Filizola M; Laakkonen L; Loew GH
    Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders.
    DiCello JJ; Carbone SE; Saito A; Pham V; Szymaszkiewicz A; Gondin AB; Alvi S; Marique K; Shenoy P; Veldhuis NA; Fichna J; Canals M; Christopoulos A; Valant C; Poole DP
    Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G66-G78. PubMed ID: 34755545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta opioid receptors in brain function and diseases.
    Chu Sin Chung P; Kieffer BL
    Pharmacol Ther; 2013 Oct; 140(1):112-20. PubMed ID: 23764370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol consumption does not impact delta and kappa opioid receptor-mediated synaptic depression in dorsolateral striatum of adult male mice.
    Muñoz B; Atwood BK
    Alcohol; 2024 Jun; 119():89-95. PubMed ID: 38857678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
    Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
    Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.
    Kruegel AC; Gassaway MM; Kapoor A; Váradi A; Majumdar S; Filizola M; Javitch JA; Sames D
    J Am Chem Soc; 2016 Jun; 138(21):6754-64. PubMed ID: 27192616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
    Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
    Mol Pharmacol; 2015 Aug; 88(2):335-46. PubMed ID: 26013541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.
    Rodríguez D; Ranganathan A; Carlsson J
    Curr Top Med Chem; 2015; 15(24):2484-503. PubMed ID: 26126906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.
    Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X
    J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Selection of DNA-Encoded Libraries for Biased Agonists of GPCRs on Live Cells.
    Cai B; El Daibani A; Bai Y; Che T; Krusemark CJ
    JACS Au; 2023 Apr; 3(4):1076-1088. PubMed ID: 37124302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for the discovery of biased GPCR ligands.
    Bermudez M; Nguyen TN; Omieczynski C; Wolber G
    Drug Discov Today; 2019 Apr; 24(4):1031-1037. PubMed ID: 30831262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.
    Filizola M; Villar HO; Loew GH
    J Comput Aided Mol Des; 2001 Apr; 15(4):297-307. PubMed ID: 11349813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-opioid receptors as targets for migraine therapy.
    Charles A; Pradhan AA
    Curr Opin Neurol; 2016 Jun; 29(3):314-9. PubMed ID: 27023737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biased ligands at opioid receptors: Current status and future directions.
    Che T; Dwivedi-Agnihotri H; Shukla AK; Roth BL
    Sci Signal; 2021 Apr; 14(677):. PubMed ID: 33824179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?
    Madariaga-Mazón A; Marmolejo-Valencia AF; Li Y; Toll L; Houghten RA; Martinez-Mayorga K
    Drug Discov Today; 2017 Nov; 22(11):1719-1729. PubMed ID: 28743488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of GPCR ligands for probing signal transduction pathways.
    Brogi S; Tafi A; Désaubry L; Nebigil CG
    Front Pharmacol; 2014; 5():255. PubMed ID: 25506327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C.
    Lee JW; Joshi S; Chan JS; Wong YH
    J Neurochem; 1998 May; 70(5):2203-11. PubMed ID: 9572309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrestin recruitment and signaling by G protein-coupled receptor heteromers.
    Mores KL; Cassell RJ; van Rijn RM
    Neuropharmacology; 2019 Jul; 152():15-21. PubMed ID: 30419245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-receptor-heteromer-specific trafficking and pharmacology.
    van Rijn RM; Whistler JL; Waldhoer M
    Curr Opin Pharmacol; 2010 Feb; 10(1):73-9. PubMed ID: 19846340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.